Search clinical trials for: First Line

Total 22259 results

Bristol-Myers Squibb

Not yet recruiting

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Healthy Volunteers
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC) | High-grade Serous Ovarian Carcinoma (HGSOC) | Uterine Serous Carcinoma (USC)

United States, Canada
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants

Healthy Volunteers

China
Peking University Cancer Hospital & Institute

Not yet recruiting

A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD

Acute Graft Versus Host Disease
Zaparackas and Knepper LTD
Northwestern University Feinberg School of Medicine

Not yet recruiting

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal Cancer | Esophageal Neoplasms | Gastroesophageal Adenocarcinoma | Gastroesophageal Junction
M.D. Anderson Cancer Center

Not yet recruiting

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Unresectable Melanoma

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC)

Extrapulmonary Small Cell Carcinoma

Italy
The First Affiliated Hospital of Henan University...

Not yet recruiting

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Esophageal Cancer

China
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Ningbo No. 1 Hospital

Recruiting

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Primary Central Nervous System Lymphoma

China
Peking Union Medical College Hospital

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Marginal Zone Lymphoma

China
Jin-hong Chen

Not yet recruiting

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

CRC

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer | Decitabine | Adebrelimab (SHR-1316)

China
Fudan University

Recruiting

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Advanced Breast Cancer | HR+/HER2- Breast Cancer

China
Bristol-Myers Squibb

Not yet recruiting

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Non-small Cell Lung Cancer (NSCLC)

United Kingdom
Shanghai Zhongshan Hospital

Not yet recruiting

Combining Chemoradiotherapy With Sintilimab in First-Line ICC

ICC

China
Sun Yat-sen University

Not yet recruiting

FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma (FOLFOX)

Hepatocellular Carcinoma | Immunotherapy | Second-line Treatment | Anti-angiogenic Therapy | FOLFOX Systemic Chemotherapy
University of Nairobi
ViiV Healthcare; Mylan Laboratories

Not yet recruiting

B/F/TAF to DTG/3TC Switch Study

HIV-1-infection

Kenya
King Saud University

Not yet recruiting

Effects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes

Osteoporosis | Diabetes Type 2
Anhui Provincial Cancer Hospital
Hutchison Medipharma Limited

Recruiting

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Ovarian Cancer

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Healthy Volunteers

United States
Beijing Tiantan Hospital

Not yet recruiting

Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)

Traumatic Brain Injury

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Celgene

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

Lymphoma, Follicular

United States, Australia, Brazil, Canada, Chile, France, Germany, Italy, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (LungCadX)

NSCLC

China
Bristol-Myers Squibb

Not yet recruiting

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Hepatic Impairment | Healthy Participants
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Bristol-Myers Squibb

Recruiting

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Peripheral T-cell Lymphoma

Japan
Jinghui Wang

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Cancer

China
Bristol-Myers Squibb

Not yet recruiting

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
Biotheus Inc.

Not yet recruiting

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer(TNBC)

China
Celgene

Not yet recruiting

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Healthy Participants

United States
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
XIANG YANQUN

Not yet recruiting

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Nasopharyngeal Cancer

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

HCC

China
Celgene

Recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Celgene

Not yet recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer

Gastric Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Pancreatic Adenocarcinoma | Advanced Cancer | Drug Use | Capecitabine | Oxaliplatin | First-Line | Cadonilimab | Nanoliposomal Irinotecan

China
CDR-Life AG

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Select Advanced Solid Tumors

United States, Denmark
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer

3

Subscribe